2. Academic Validation
  3. ADAM10 is a key player in the diagnosis, prognosis and metastasis of non-small cell lung cancer (NSCLC)

ADAM10 is a key player in the diagnosis, prognosis and metastasis of non-small cell lung cancer (NSCLC)

  • J Cancer. 2025 Feb 11;16(5):1736-1746. doi: 10.7150/jca.107236.
Wenqian Zhang 1 2,  Liyao Yang 3,  Mufan Li 1 2,  Lianmei Zhang 2 4,  Jingliang Cheng 2,  Ali H El-Far 2,  Youhua Xu 1,  Junjiang Fu 1 2
Affiliations

Affiliations

  • 1 Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macao 999078, China.
  • 2 Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, Sichuan Province, China.
  • 3 Department of Oncology, The First People's Hospital of Loudi City, Loudi 417009, Hunan Province, China.
  • 4 Department of Pathology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China.
PMID: 39991567 DOI: 10.7150/jca.107236
Abstract

A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) plays critical roles in various cancer-associated biological events, such as cell multiplication, migration, and metastasis. This study employs both the TCGA database and patient samples to demonstrate that ADAM10 is highly expressed in non-small cell lung Cancer (NSCLC) compared with normal tissue at different stages. Increased ADAM10 expression is positively correlated with decreased overall and recurrence-free survival. On the functional front, overexpression of ADAM10 promotes lung Cancer cell progression, migration, and invasion, whereas downregulation of ADAM10 inhibits these processes. Mechanically, ADAM10 modulates the expression of Notch1, MMP9 and EMT markers such as Vimentin, N-Cadherin, and E-cadherin. Overall, our findings suggest that ADAM10 may be a promising therapeutic and prognostic marker for NSCLC, emphasizing the importance of regulating its expression.

Keywords

DAM10; Non-small cell lung cancers; Prognostics.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-19956
    99.67%, ADAM10/MMP9 Inhibitor
    MMP